

AMENDMENTSAmendments to the claims:

Please enter the amendments to claims 74, 83, 84, 106, 118, and 124 and please enter new claims 129-168 as set forth in the complete listing of the claims that follows. This complete listing of the claims replaces previous claim listings.

1-73 (cancelled).

74 (previous presented). A method for determining the sequence in one or more sequence variations in a target nucleic acid, comprising:

(a) providing mass signals of fragments resulting from (i) one specific cleavage of a target nucleic acid and a reference nucleic acid into fragments, and (ii) determining mass signals of the fragments;

(b) identifying differences in mass signals between target nucleic acid fragments and reference nucleic acid fragments, thereby identifying different fragments;

(c) generating one or more compomer witnesses corresponding to each different fragment identified in (b); and

(d) identifying a reduced set of candidate sequence variations corresponding to the compomer witnesses, whereby the one or more sequence variations in the target nucleic acid are determined from the candidate sequence variations.

75 (previous presented). The method of claim 74, wherein the differences in mass signals in (b) are selected from the group consisting of missing signals, additional signals, signals that are different in intensity and signals having a different signal-to-noise ratio.

76 (previous presented). The method of claim 74, wherein the mass signals are determined by mass spectrometry.

77 (previous presented). The method of claim 74, wherein two or more sequence variations are determined.

78 (previous presented). The method of claim 74, wherein the sequence variation is at one or more base positions.

79 (previous presented). The method of claim 74, wherein the sequence variation is a mutation or a polymorphism.

80 (previous presented). The method of claim 79, wherein the mutation is an insertion, a deletion or a substitution.

81 (previous presented). The method of claim 74, wherein the polymorphism is a single nucleotide polymorphism.

82 (previous presented). The method of claim 74, wherein the target nucleic acid is from an organism selected from the group consisting of eukaryotes, prokaryotes and viruses.

83 (currently amended). The method of claim ~~[[86]]~~ 82, wherein the organism is a bacterium.

84 (currently amended). The method of claim ~~[[87]]~~ 83, wherein the bacterium is selected from the group consisting of *Helicobacter pylori*, *Borrelia burgdorferi*, *Legionella pneumophila*, *Mycobacteria* sp. (e.g. *M. tuberculosis*, *M. avium*, *M. intracellulare*, *M. kansasii*, *M. goodii*), *Staphylococcus aureus*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Listeria monocytogenes*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus* sp., *Streptococcus faecalis*, *Streptococcus bovis*, *Streptococcus pneumoniae*, *Campylobacter* sp., *Enterococcus* sp., *Haemophilus influenzae*, *Bacillus anthracis*, *Corynebacterium diphtheriae*, *Corynebacterium* sp., *Erysipelothrix rhusiopathiae*, *Clostridium perfringens*, *Clostridium tetani*, *Enterobacter aerogenes*, *Klebsiella pneumoniae*, *Pasteurella multocida*, *Bacteroides* sp., *Fusobacterium nucleatum*,

Streptobacillus moniliformis, *Treponema pallidum*, *Treponema pertenu*, *Leptospira* and *Actinomyces israeli*.

85 (previous presented). The method of claim 74, which further comprises (i) providing a target nucleic acid and a reference nucleic acid; (ii) generating fragments of the target nucleic acid and the reference nucleic acid by specific cleavage; and (iii) determining mass signals of the fragments, wherein the mass signals of (iii) are provided in (a).

86 (previous presented). The method of claim 85, wherein the target nucleic acid is in a mixture of nucleic acids.

87 (previous presented). The method of claim 85, wherein the mixture comprises the reference nucleic acid.

88 (previous presented). The method of claim 85, wherein the mixture comprises a plurality of reference nucleic acids.

89 (previous presented). The method of claim 85, wherein the mixture comprises a plurality of target nucleic acids.

90 (previous presented). The method of claim 85, wherein one specific cleavage agent is utilized to generate fragments.

91 (previous presented). The method of claim 85, wherein two or more specific cleavage agents are utilized to generate fragments.

92 (previous presented). The method of claim 85, wherein specific cleavage comprises treatment with an RNase.

93 (previous presented). The method of claim 85, wherein specific cleavage comprises treatment with a specific cleavage agent selected from the group consisting of

RNase T1, RNase U2, the RNase PhyM, RNase A, chicken liver RNase (RNase CL3) and cusavitin.

94 (previous presented). The method of claim 85, wherein specific cleavage comprises treatment with a glycosylase.

95 (previous presented). The method of claim 85, wherein the target nucleic acid is in a pool of nucleic acids from individuals.

96 (previous presented). The method of claim 85, wherein the target nucleic acid is genomic DNA from a single individual.

97 (previous presented). The method of claim 85, wherein the target nucleic acid is selected from the group consisting of single stranded DNA, double stranded DNA, cDNA, single stranded RNA, double stranded RNA, DNA/RNA hybrid, PNA and a DNA/RNA mosaic nucleic acid.

98 (previous presented). The method of claim 85, wherein the target nucleic acid is produced by transcription.

99 (previous presented). The method of claim 85, wherein the mass signals are generated by mass spectrometry.

100 (previous presented). The method of claim 74, wherein fragments are generated by simulated specific cleavage.

101 (previous presented). The method of claim 74, wherein fragments of the reference nucleic acid are generated by simulated specific cleavage.

102 (previous presented). The method of claim 74, wherein sequence variations in the target biomolecule permit genotyping a subject, forensic analysis, disease diagnosis or disease prognosis.

103 (previous presented). The method of claim 74, wherein the method determines epigenetic changes in a target nucleic acid molecule relative to a reference nucleic acid molecule.

104 (previous presented). The method of claim 74, wherein the target nucleic acid is from a tumor sample.

105 (previous presented). The method of claim 76, wherein compomer witnesses are generated based upon parameters selected from the group consisting of mass of the different fragment, peak separation between fragments whose masses differ by a single nucleotide in type or length, and mass spectrometer resolution.

106 (currently amended). The method of claim 74, wherein sequence variations in (d) are determined according to one or more ~~reference~~candidate sequences having at most k sequence variations.

107 (previous presented). The method of claim 106, wherein k is one or two.

108 (previous presented). The method of claim 106, wherein k is three or more.

109 (previous presented). The method of claim 74, further comprising: (e) scoring the candidate sequence variations, whereby a sequence variation in the target nucleic acid is determined from the candidate sequence variation scoring in (e).

110 (previous presented). The method of claim 109, wherein a simulated spectrum is generated for each sequence variation candidate, and each spectrum is scored.

111 (previous presented). The method of claim 109, wherein scores assigned to a sequence variation candidate for multiple target nucleic acids are combined for an overall score of the sequence variation candidate.

112 (previous presented). The method of claim 74, wherein sequence variation in the target nucleic acid is recorded in a record.

113 (previous presented). The method of claim 74, wherein the one or more compomer witnesses for each different fragment have a mass within a mass difference from the actual mass of the different fragment.

114 (previous presented). The method of claim 113, wherein the mass difference is the resolution of mass measurement.

115 (previous presented). A method for detecting one or more sequence variations in a target nucleic acid, comprising:

(a) providing a plurality of fragmentation patterns resulting from (i) specific cleavage of a sample comprising a target nucleic acid by multiple cleavage reactions, wherein the target nucleic acid is in a nucleic acid mixture, and specific cleavage of a reference nucleic acid by the same cleavage reactions; and (ii) determining mass signals of the fragments;

(b) identifying differences in mass signals between the plurality of fragmentation patterns of target nucleic acid fragments and reference nucleic acid fragments, thereby identifying different fragments;

(c) identifying different fragments that are consistent with a particular sequence variation in the target nucleic acid;

(d) combining the consistent different fragments of (c) to obtain a spectrum of different fragments;

(e) generating from the spectrum of different fragments of (d) one or more compomer witnesses corresponding to each of the different fragments;

(f) determining sequence variations that are candidate sequences corresponding to the compomer witnesses;

(g) scoring the candidate sequences of (f); and

(h) determining one or more sequence variations in the target nucleic acid.

116 (previous presented). The method of claim 115, wherein the mass signals are determined by mass spectrometry.

117 (previous presented). The method of claim 115, wherein compomer witnesses are generated based upon parameters selected from the group consisting of mass of the different fragment, peak separation between fragments whose masses differ by a single nucleotide in type or length, and mass spectrometer resolution.

118 (currently amended). The method of claim 115, wherein sequence variations in (f) are determined according to one or more ~~reference~~candidate sequences having at most k sequence variations.

119 (previous presented). The method of claim 118, wherein k is one or two.

120 (previous presented). The method of claim 118, wherein k is three or more.

121 (previous presented). The method of claim 115, wherein one or more sequence variations are recorded in a record.

122 (previous presented). The method of claim 115, wherein the one or more compomer witnesses for each different fragment have a mass within a mass difference from the actual mass of the different fragment.

123 (previous presented). The method of claim 122, wherein the mass difference is the resolution of mass measurement.

124 (currently amended). A method for detecting one or more sequence variations in a target nucleic acid, comprising:

(a) providing reference sequence s, a description of cleavage reaction conditions, whether modified nucleotides or amino acids are incorporated into all or part of the target sequence, a list of signals corresponding to different fragments between target nucleic acid fragments and reference nucleic acid fragments, and maximal sequence variation order k;

(b) generating a list of sequence variations that contain at most k insertions, deletions, and substitutions, and that have a different peak as a witness;

generating one or more compomer witnesses c' corresponding to each different fragment identified in (a); and

(d) identifying a reduced set of candidate sequence variations corresponding to the compomer witnesses represented by $C_k := \{ (c[i, j], b[i, j]) : 1 \leq i \leq \text{length of } s, \text{ and } \text{ord}[i, j] + \#b[i, j] \leq k \}$, where C is a set of all bounded compomers within a string s , $c[i, j]$ is a compomer corresponding to substring $s[i, j]$, $b[i, j]$ is a boundary of the substring $s[i, j]$, and whereby the one or more sequence variations in the target nucleic acid are determined from the candidate sequence variations.

(c) computing bounded compomers $(c[i, j], b[i, j])$ in $C.\text{sub}.k$, and store the bounded compomers together with the indices i, j based on the reference sequence s and the specific cleavage reaction;

(d) identifying compomers for each different signal having a mass close to the signal mass by a sufficiently small mass difference, and store the compomers as compomer witnesses;

(e) for each compomer witness c' , identifying bounded compomers (c, b) in $C.\text{sub}.k$, wherein $D(c', c, b)$ is less than or equal to k ;

(f) outputting sequence variations of s to a new reference sequence s' using at most k insertions, deletions, and substitutions for each bounded compomer (c, b) with indices i, j ,

wherein:

a nucleotide is inserted or substituted at a cleaved base directly before position i if L is in b ;

a nucleotide is inserted or substituted at a cleaved base directly after position j if R is in b ;

at most $k - \#b$ insertions, deletions, and insertions are used that transform the fragment $f = s[i, j]$ with corresponding compomer c into a fragment f' of s' with corresponding compomer c' ;

boundary $b[i, j]$ of the substring $s[i, j]$ or the corresponding compomer $c[i, j]$ refers to a set of markers indicating whether cleavage of string s does not take place immediately outside the substring $s[i, j]$;

marker L indicates s is not cleaved directly before i ;

marker R_i indicates s is not cleaved directly after j ;
 $\#b$ denotes the number of elements in the set b ;
 $b[i,j]$ is a subset of the set $\{L,R\}$ and denotes the boundary of $s[i,j]$ as defined by the following:

$b[i,j] := \{L,R\}$ if s is neither cleaved directly before i nor after j ;

$b[i,j] := \{R\}$ if s is cleaved directly before i , but not after j ;

$b[i,j] := \{L\}$ if s is cleaved directly after j , but not before i ;

$b[i,j] := \{\}$ if s is cleaved directly before i and after j ; and

$\#b[i,j]$ denotes the number of elements of the set $b[i,j]$;

$C.sub.k := \{(c[i,j], b[i,j]) : 1 \leq i \leq j \leq \text{length of } s, \text{ and}$

$\text{ord}[i,j] + \#b[i,j] \leq k\}$; $\text{ord}[i,j]$ is the number of times the fragment $s[i,j]$ is cleaved;

and

$D(c', c, b)$ is the distance between a compomer witness c' and a bounded compomer (c, b) and $D(c', c, b) := d(c', c) + \#b$.

125 (previously presented). The method of claim 124, wherein k is 1 or 2.

126 (previously presented). The method of claim 124, wherein k is 3.

127 (previously presented). The method of claim 124, wherein one or more sequence variations are recorded in a record.

128 (previously presented). The method of claim 124, wherein the sufficiently small mass difference is the resolution of mass measurement.

129. (new). A method for determining one or more sequence variations in a target nucleic acid, comprising:

(a) providing mass signals of fragments resulting from (i) specific cleavage of a target nucleic acid and a reference nucleic acid into fragments, and (ii) determining mass signals of the fragments;

(b) identifying differences in mass signals between target nucleic acid fragments and reference nucleic acid fragments, thereby identifying different fragments;

(c) generating one or more compomer witnesses corresponding to each different fragment identified in (b); and

(d) identifying a reduced set of candidate sequence variations corresponding to the compomer witnesses represented by $C_k := \{c[i, j], b[i, j] : 1 \leq i \leq j \leq \text{length of } s, \text{ and } \text{ord}[i, j] + \#b[i, j] \leq k\}$, where C is a set of all bounded compomers within a string s , $c[i, j]$ is a compomer corresponding to substring $s[i, j]$, $b[i, j]$ is a boundary of the substring $s[i, j]$, and whereby the one or more sequence variations in the target nucleic acid are determined from the candidate sequence variations.

130. (new). The method of claim 129, wherein the differences in mass signals in (b) are selected from the group consisting of missing signals, additional signals, signals that are different in intensity and signals having a different signal-to-noise ratio.

131 (new). The method of claim 129, wherein the mass signals are determined by mass spectrometry.

132 (new). The method of claim 129, wherein two or more sequence variations are determined.

133 (new). The method of claim 129, wherein the sequence variation is at one or more base positions.

134 (new). The method of claim 129, wherein the sequence variation is a mutation or a polymorphism.

135 (new). The method of claim 134, wherein the mutation is an insertion, a deletion or a substitution.

136 (new). The method of claim 129, wherein the polymorphism is a single nucleotide polymorphism.

137 (new). The method of claim 129, wherein the target nucleic acid is from an organism selected from the group consisting of eukaryotes, prokaryotes and viruses.

138 (new). The method of claim 137, wherein the organism is a bacterium.

139 (new). The method of claim 138, wherein the bacterium is selected from the group consisting of *Helicobacter pylori*, *Borrelia burgdorferi*, *Legionella pneumophila*, *Mycobacteria* sp (e.g. *M. tuberculosis*, *M. avium*, *M. intracellulare*, *M. kansaii*, *M. gordonae*), *Staphylococcus aureus*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Listeria monocytogenes*, *Streptococcus pyogenes*, *Streptococcus agalactiae*, *Streptococcus* sp., *Streptococcus faecalis*, *Streptococcus bovis*, *Streptococcus pneumoniae*, *Campylobacter* sp., *Enterococcus* sp., *Haemophilus influenzae*, *Bacillus anthracis*, *Corynebacterium diphtheriae*, *Corynebacterium* sp., *Erysipelothrix rhusiopathiae*, *Clostridium perfringens*, *Clostridium tetani*, *Enterobacter aerogenes*, *Klebsiella pneumoniae*, *Pasturella multocida*, *Bacteroides* sp., *Fusobacterium nucleatum*, *Streptobacillus moniliformis*, *Treponema pallidum*, *Treponema pertenuis*, *Leptospira* and *Actinomyces israelii*.

140 (new). The method of claim 129, which further comprises (i) providing a target nucleic acid and a reference nucleic acid; (ii) generating fragments of the target nucleic acid and the reference nucleic acid by specific cleavage; and (iii) determining mass signals of the fragments, wherein the mass signals of (iii) are provided in (a).

141 (new). The method of claim 140, wherein the target nucleic acid is in a mixture of nucleic acids.

142 (new). The method of claim 140, wherein the mixture comprises the reference nucleic acid.

143 (new). The method of claim 140, wherein the mixture comprises a plurality of reference nucleic acids.

144 (new). The method of claim 140, wherein the mixture comprises a plurality of target nucleic acids.

145 (new). The method of claim 140, wherein one specific cleavage agent is utilized to generate fragments.

146 (new). The method of claim 140, wherein two or more specific cleavage agents are utilized to generate fragments.

147 (new). The method of claim 140, wherein specific cleavage comprises treatment with an RNase.

148 (new). The method of claim 140, wherein specific cleavage comprises treatment with a specific cleavage agent selected from the group consisting of RNase T1, RNase U2, the RNase PhyM, RNase A, chicken liver RNase (RNase CL3) and cusavitin.

149 (new). The method of claim 140, wherein specific cleavage comprises treatment with a glycosylase.

150 (new). The method of claim 140, wherein the target nucleic acid is in a pool of nucleic acids from individuals.

151 (new). The method of claim 140, wherein the target nucleic acid is genomic DNA from a single individual.

152 (new). The method of claim 140, wherein the target nucleic acid is selected from the group consisting of single stranded DNA, double stranded DNA, cDNA, single stranded RNA, double stranded RNA, DNA/RNA hybrid, PNA and a DNA/RNA mosaic nucleic acid.

153 (new). The method of claim 140, wherein the target nucleic acid is produced by transcription.

154 (new). The method of claim 140, wherein the mass signals are generated by mass spectrometry.

155 (new). The method of claim 129, wherein sequence variations in the target biomolecule permit genotyping a subject, forensic analysis, disease diagnosis or disease prognosis.

156 (new). The method of claim 129, wherein the method determines epigenetic changes in a target nucleic acid molecule relative to a reference nucleic acid molecule.

157 (new). The method of claim 129, wherein the target nucleic acid is from a tumor sample.

158 (new). The method of claim 131, wherein compomer witnesses are generated based upon parameters selected from the group consisting of mass of the different fragment, peak separation between fragments whose masses differ by a single nucleotide in type or length, and mass spectrometer resolution.

159 (new). The method of claim 129, wherein sequence variations in (d) are determined according to one or more candidate sequences having at most k sequence variations.

160 (new). The method of claim 159, wherein k is one or two.

161 (new). The method of claim 159, wherein k is three or more.

162 (new). The method of claim 129, further comprising: (e) scoring the candidate sequence variations, whereby a sequence variation in the target nucleic acid is determined from the candidate sequence variation scoring in (e).

163 (new). The method of claim 162, wherein a simulated spectrum is generated for each sequence variation candidate, and each spectrum is scored.

164 (new). The method of claim 162, wherein scores assigned to a sequence variation candidate for multiple target nucleic acids are combined for an overall score of the sequence variation candidate.

165 (new). The method of claim 129, wherein sequence variation in the target nucleic acid is recorded in a record.

166 (new). The method of claim 129, wherein the one or more compomer witnesses for each different fragment have a mass within a mass difference from the actual mass of the different fragment.

167 (new). The method of claim 166, wherein the mass difference is the resolution of mass measurement.

168. (new). The method of claim 74, wherein the reference sequence is unknown.